Build status - In Progress
Study Evaluating the Efficacy of Synergo Radiofrequency-Induced Thermochemotherapy Effect (RITE) with Mitomycin C (Synergo RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC)
Recruiting
18 years - 99 years
All
Phase
3
10 participants needed
1 Location
Brief description of study
The objectives of the study are to determine the efficacy and safety of Synergo® RITE and mitomycin C (MMC) in the treatment of carcinoma in situ (CIS) non-muscle invasive bladder cancer in adult patients who didn't respond to 2 courses of treatment with Bacillus Calmette-Guérin (BCG) installations. The Synergo® system is designed for the treatment of NMIBC. Radio waves, emanating from a small antenna embedded in the special disposable Synergo® catheter, continuously heat the bladder walls, while a chemotherapeutic agent (e.g., MMC) is continuously circulated between the bladder and the computer-embedded Synergo® radiofrequency hyperthermia device.
The study will consist of three periods: 1) Screening; 2) Induction treatment (8 weekly treatments of Synergo® RITE + MMC), and 3) Maintenance treatment and follow-up (one Synergo® RITE + MMC treatment every 6 weeks).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832005
Find a site
,
Your Information has been sent successfully.
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or